Developing Story
QuidelOrtho – Testing Unit Sale & Post-COVID Diagnostic Sector Consolidation (2026)
QuidelOrtho is reportedly exploring the sale of a testing unit amid PE interest in healthcare assets, with its shares down ~90% from COVID-era highs. The situation illustrates the broader distress-driven consolidation occurring in the post-pandemic diagnostics sector.
Importance: 65%Confidence: 78%Mentions: 1Updated: June 28, 2026
## QuidelOrtho – Testing Unit Sale & Post-COVID Diagnostic Sector Consolidation (2026)
### Overview
QuidelOrtho is reportedly looking to sell a testing unit as private equity firms circle healthcare companies, according to the Financial Times (June 27, 2026). The company's shares are down approximately 90% since its rapid antigen tests were among the first approved for COVID-19.
### Company Background
QuidelOrtho was formed from the merger of Quidel Corporation and Ortho Clinical Diagnostics in 2022, creating a large diagnostics platform. Its COVID-19 rapid antigen tests generated extraordinary revenue during the pandemic, which subsequently collapsed as demand normalized.
### Asset Sale Context
- The 90% share price decline reflects the mismatch between pandemic-era valuations and normalized diagnostic demand.
- Private equity interest suggests buyers see value in the underlying diagnostic infrastructure at distressed valuations.
- The specific unit being considered for sale has not been identified in available reporting (FT, June 27).
### Sector Narrative
QuidelOrtho is emblematic of a broader pattern: COVID diagnostic companies that achieved peak valuations in 2020–2022 now face structural overcapacity, revenue normalization, and strategic asset shedding. This is an active M&A environment for diagnostic assets.
### Legal & Strategic Considerations
- PE acquirers will conduct extensive diligence on FDA regulatory status of acquired testing platforms.
- Antitrust review unlikely given market fragmentation post-COVID.
- Potential regulatory liability related to COVID test accuracy claims may affect deal structuring.
### Watch
- Identification of the specific unit for sale and buyer process.
- PE firm involvement and deal structure.
- Comparable transactions in the diagnostics sector.